Prevention of Paclitaxel Neuropathy With Cryotherapy

Status unconfirmed · Phase 2

Conditions studied: Breast Cancer

In brief

The purpose of this study is to determine if cryotherapy can effectively decrease the rate of neuropathy in patients undergoing weekly paclitaxel treatments.

Key facts

Study ID

NCT02230319

Run by

Medical Oncology & Hematology Associates of Northern Virginia

People needed

39

Starts

2014-10-01

Expected to finish

2017-03-01

Last updated by the study team

2015-10-01

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women 18 years of age or older
• Histologically or cytological proven diagnosis of breast cancer Stage I- III.
• Must pl an to receive weekly paclitaxel treatment in either the adjuvant or neoadjuvant setting.
• May have received prior treatment including, radiation, surgery chemotherapy hormone and biologics.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Patient signed informed consent.
• Patient willing and able to comply with scheduled visits and treatment plan.

You may not qualify if…

• Patient presents with Grade 2 or greater peripheral neuropathy.
• History of Raynaud's Disease.
• Patient presents open or poorly-healing wounds on the hands or feet.
• Patients with cold intolerance.
• Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate patient participation.

Where it is running

• Medical Oncology & Hematology Associates of Northern Virginia — Fairfax, Virginia, United States
• Medical Oncology & Hematology Associates of Northern Virginia — Reston, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.